Melanoma: trials for referral

Where the open trials are

Type a city to sort by distance. The distance is worked out in your browser; the city is not sent anywhere.

Registry facts, one per line, newest first.

• 5 Nov 2026

  Closed for recruitment

  A Study of ST-1898 for Unresectable or Metastatic Melanoma

  NCT06359860 · Phase 1/2 · China

  Source: ClinicalTrials.gov
• 24 Aug 2026

  Phase changed: Phase 3 → Phase 1

  Pharmacokinetic Similarity Study to Compare AVT32-DRL_PB With Keytruda® in Participants With Fully Resected Melanoma

  NCT07475572 · Phase 1 · Spain, Romania, Ukraine

  Source: ClinicalTrials.gov
• 26 Aug 2026

  Opened for recruitment

  Neoadjuvant Pembrolizumab in Patients With Stage IIb/c Melanoma

  NCT07349303 · Phase 2 · Sweden

  Source: ClinicalTrials.gov
• 19 Aug 2026

  Opened for recruitment

  A Long-Term Follow-Up Study of Subjects Completing the AU-011-301(CoMpass) for Early Choroidal Melanoma

  NCT07338968 · Phase 3 · Austria, Belgium, Czechia, Germany, Spain, France

  Source: ClinicalTrials.gov
• 1 Oct 2026

  Status changed: Completed → Running, not recruiting

  A Study of Lifileucel (Tumor-infiltrating Lymphocytes) in Adults With Advanced Melanoma

  NCT07288203 · Phase 2 · Australia, Canada, Germany, Spain, France, United Kingdom

  Source: ClinicalTrials.gov
• 29 Oct 2026

  Opened for recruitment

  DB-1311 in Combination With BNT327 or DB-1305 in Advanced/Metastatic Solid Tumors

  NCT06953089 · Phase 2 · Australia, China, Germany, Spain, France, Italy

  Source: ClinicalTrials.gov
• 5 Mar 2026

  Status changed: Completed → Running, not recruiting

  TNFα and IL-2 Coding Oncolytic Adenovirus TILT-123 With Lymphocyte-depleting Chemotherapy and TILs in the Treatment of Melanoma

  NCT06961786 · Phase 1 · Denmark

  Source: ClinicalTrials.gov
• 13 Jul 2026

  Opened for recruitment

  A Study to Learn About the Long-Term Health of Adult Participants From a Previous Study of a New Melanoma Treatment

  NCT06848088 · Phase 2 · Ireland, United States

  Source: ClinicalTrials.gov
• 20 Jan 2025

  Opened for recruitment

  T-cell Therapy with CRISPR PD1-edited Tumor Infiltrating Lymphocytes for Patients with Metastatic Melanoma

  NCT06783270 · Phase 1 · Denmark

  Source: ClinicalTrials.gov
• 2 Apr 2026

  Opened for recruitment

  A Randomized, Phase 2/3 Study to Investigate the Efficacy and Safety of RP2 in Combination With Nivolumab in Immune Checkpoint Inhibitor-Naïve Adult Patients With Metastatic Uveal Melanoma

  NCT06581406 · Phase 2/3 · Australia, Germany, Spain, France, United Kingdom, Italy

  Source: ClinicalTrials.gov
• 12 Nov 2025

  Status changed: Completed → Running, not recruiting

  A Study of Cobolimab Plus Dostarlimab in Pediatric and Young Adult Participants With Cancer

  NCT06521567 · Phase 1/2 · Czechia, Germany, Denmark, Spain, France, Italy

  Source: ClinicalTrials.gov
• 18 Aug 2026

  Opened for recruitment

  Assessment of PET Tracers to Evaluate T Cell Change and Activation in Relation to Immunotherapy Treatment Response in Non-Small Cell Lung Cancer

  NCT06457789 · Phase 2/3 · Netherlands

  Source: ClinicalTrials.gov
• 27 Feb 2026

  Closed for recruitment

  A Study to Assess Naporafenib (ERAS-254) Administered With Trametinib in Patients With NRAS-mutant Melanoma (SEACRAFT-2)

  NCT06346067 · Phase 3 · Australia, Belgium, Canada, Czechia, Germany, Denmark

  Source: ClinicalTrials.gov
• 28 Apr 2026

  Opened for recruitment

  A First-In Human (FIH) Study to Find Out How Well REGN10597 Medicine Given Alone or in Combination With Cemiplimab Works in Adult Participants Who Have Cancer With Tumors That Have Spread in Their Body

  NCT06413680 · Phase 1/2 · Germany, Spain, France, Italy, United States

  Source: ClinicalTrials.gov
• 14 Nov 2024

  Phase changed: Phase 2 → Phase 1/2

  Intradermal Ipilimumab and Nivolumab in High Risk Stage II Melanoma

  NCT06240143 · Phase 1/2 · Germany, Netherlands, Sweden

  Source: ClinicalTrials.gov
• 10 Feb 2026

  Closed for recruitment

  A Trial to Learn if Fianlimab and Cemiplimab Are Safe and Work Better Than Anti-PD1 Alone in Adult Participants With Resectable Stage 3 or 4 Melanoma

  NCT06190951 · Phase 2 · Austria, Australia, Canada, Germany, Spain, France

  Source: ClinicalTrials.gov
• 8 Apr 2026

  Status changed: Completed → Running, not recruiting

  A Study of Participant Reported Preference for Subcutaneous Pembrolizumab Coformulated With Berahyaluronidase Alfa (MK-3475A) Over Intravenous Pembrolizumab (MK-3475) Formulation in Multiple Tumor Types (MK-3475A-F11)

  NCT06099782 · Phase 2 · Argentina, Australia, Chile, France, Japan, New Zealand

  Source: ClinicalTrials.gov
• 13 Oct 2026

  Closed for recruitment

  A Phase 3 Randomized, Masked, Controlled Trial to Evaluate Efficacy and Safety of Belzupacap Sarotalocan (AU-011) Treatment Compared to Sham Control in Subjects With Primary Indeterminate Lesions or Small Choroidal Melanoma

  NCT06007690 · Phase 3 · Austria, Australia, Belgium, Canada, Czechia, Germany

  Source: ClinicalTrials.gov
• 18 Aug 2026

  Opened for recruitment

  A Clinical Imaging Study of the Changes in [18F]F-AraG Uptake Following Anti-PD-1 Therapy in Non-small Cell Lung Cancer

  NCT05701176 · Phase 1/2 · Netherlands

  Source: ClinicalTrials.gov
• 21 Nov 2025

  Phase changed: Phase 1/2 → Phase 1

  A Study to Characterize the Safety, Tolerability, and Preliminary Efficacy of CFT1946 as Monotherapy and Combination Therapy in Subjects With BRAF V600 Mutant Solid Tumors

  NCT05668585 · Phase 1 · Germany, Spain, France, United Kingdom, Italy, United States

  Source: ClinicalTrials.gov
• 26 Aug 2026

  Closed for recruitment

  A Study of Subcutaneous Nivolumab + Relatlimab Fixed-dose Combination (FDC) in Previously Untreated Metastatic or Unresectable Melanoma

  NCT05625399 · Phase 3 · Austria, Australia, Belgium, Brazil, Canada, Switzerland

  Source: ClinicalTrials.gov
• 25 Feb 2026

  Phase changed: Phase 2/3 → Phase 3

  Tebentafusp Regimen Versus Investigator's Choice in Previously Treated Advanced Melanoma (TEBE-AM)

  NCT05549297 · Phase 3 · Austria, Australia, Belgium, Canada, Switzerland, Germany

  Source: ClinicalTrials.gov
• 30 Sept 2026

  Closed for recruitment

  A Clinical Trial of Regorafenib in Patients With Pretreated Advanced Melanoma

  NCT05370807 · Phase 2 · Belgium

  Source: ClinicalTrials.gov
• 12 May 2026

  Opened for recruitment

  START: Safety and Anti-Tumor Activity of PeptiCRAd-1 in Treatment of Cancer

  NCT05492682 · Phase 1 · Germany, Italy

  Source: ClinicalTrials.gov
• 30 Mar 2025

  Opened for recruitment

  Open Label Phase 2 Basket Trial With Atezolizumab and Tiragolumab in Solid Tumors

  NCT05483400 · Phase 2 · Netherlands

  Source: ClinicalTrials.gov
• 28 Aug 2025

  Status changed: Completed → Running, not recruiting

  IO102-IO103 in Combination With Pembrolizumab Versus Pembrolizumab Alone in Advanced Melanoma (IOB-013 / KN-D18)

  NCT05155254 · Phase 3 · Australia, Belgium, Czechia, Germany, Denmark, Spain

  Source: ClinicalTrials.gov
• 30 Sept 2026

  Status changed: Completed → Running, not recruiting

  A Study to Evaluate the Safety and Activity of Belvarafenib as a Single Agent and in Combination With Either Cobimetinib or Cobimetinib Plus Nivolumab in Patients With NRAS-mutant Advanced Melanoma.

  NCT04835805 · Phase 1 · Australia, Canada, Germany, South Korea, Norway, United States

  Source: ClinicalTrials.gov
• 18 Jun 2026

  Closed for recruitment

  Combination or Sequence of Vemurafenib, Cobimetinib, and Atezolizumab in High-risk, Resectable Melanoma

  NCT04722575 · Phase 2 · Italy

  Source: ClinicalTrials.gov
• 4 Aug 2026

  Status changed: Completed → Running, not recruiting

  GEN1042 Safety Trial and Anti-tumor Activity in Participants With Malignant Solid Tumors

  NCT04083599 · Phase 1/2 · Germany, Denmark, Spain, France, United Kingdom, Georgia

  Source: ClinicalTrials.gov
• 23 Sept 2026

  Status changed: Completed → Running, not recruiting

  ADP-A2M4CD8 as Monotherapy or in Combination With Either Nivolumab or Pembrolizumab in HLA-A2+ Subjects With MAGE-A4 Positive Tumors (SURPASS)

  NCT04044859 · Phase 1 · Canada, Spain, United States

  Source: ClinicalTrials.gov
• 25 Apr 2024

  Phase changed: Phase 2 → Phase 1/2

  Evaluating the Effect of Nivolumab for Patients With In-transit Metastases Treated With Isolated Limb Perfusion

  NCT03685890 · Phase 1/2 · Netherlands, Sweden

  Source: ClinicalTrials.gov
• 13 Jul 2023

  Opened for recruitment

  Melanoma Metastasized to the Brain and Steroids

  NCT03563729 · Phase 2 · Denmark

  Source: ClinicalTrials.gov
• 7 May 2026

  Closed for recruitment

  Melanoma Metastasized to the Brain and Steroids

  NCT03563729 · Phase 2 · Denmark

  Source: ClinicalTrials.gov
• 8 Oct 2026

  Opened for recruitment

  A Phase 3 Randomized, Masked, Controlled Trial to Evaluate Efficacy and Safety of Belzupacap Sarotalocan (AU-011) Treatment Compared to Sham Control in Subjects With Primary Indeterminate Lesions or Small Choroidal Melanoma

  NCT06007690 · Phase 3 · Austria, Australia, Belgium, Canada, Czechia, Germany

  Source: ClinicalTrials.gov
• 2 Feb 2026

  Opened for recruitment

  A Study to Assess Naporafenib (ERAS-254) Administered With Trametinib in Patients With NRAS-mutant Melanoma (SEACRAFT-2)

  NCT06346067 · Phase 3 · Australia, Belgium, Canada, Czechia, Germany, Denmark

  Source: ClinicalTrials.gov
• 16 Sept 2024

  Closed for recruitment

  T-cell Therapy with CRISPR PD1-edited Tumor Infiltrating Lymphocytes for Patients with Metastatic Melanoma

  NCT06783270 · Phase 1 · Denmark

  Source: ClinicalTrials.gov
• 17 Mar 2025

  Opened for recruitment

  A Clinical Trial of Regorafenib in Patients With Pretreated Advanced Melanoma

  NCT05370807 · Phase 2 · Belgium

  Source: ClinicalTrials.gov
• 30 Sept 2026

  Opened for recruitment

  Combination or Sequence of Vemurafenib, Cobimetinib, and Atezolizumab in High-risk, Resectable Melanoma

  NCT04722575 · Phase 2 · Italy

  Source: ClinicalTrials.gov
• 18 Sept 2026

  Opened for recruitment

  A Trial to Learn if Fianlimab and Cemiplimab Are Safe and Work Better Than Anti-PD1 Alone in Adult Participants With Resectable Stage 3 or 4 Melanoma

  NCT06190951 · Phase 2 · Austria, Australia, Canada, Germany, Spain, France

  Source: ClinicalTrials.gov
• 4 Nov 2024

  Closed for recruitment

  Open Label Phase 2 Basket Trial With Atezolizumab and Tiragolumab in Solid Tumors

  NCT05483400 · Phase 2 · Netherlands

  Source: ClinicalTrials.gov
• 19 Jun 2025

  Status changed: Recruiting → Not yet recruiting

  Neoadjuvant Pembrolizumab in Patients With Stage IIb/c Melanoma

  NCT07349303 · Phase 2 · Sweden

  Source: ClinicalTrials.gov
• 2 Jun 2026

  Status changed: By invitation only → Not yet recruiting

  A Study to Learn About the Long-Term Health of Adult Participants From a Previous Study of a New Melanoma Treatment

  NCT06848088 · Phase 2 · Ireland, United States

  Source: ClinicalTrials.gov
• 27 Aug 2026

  Status changed: Recruiting → Not yet recruiting

  A Randomized, Phase 2/3 Study to Investigate the Efficacy and Safety of RP2 in Combination With Nivolumab in Immune Checkpoint Inhibitor-Naïve Adult Patients With Metastatic Uveal Melanoma

  NCT06581406 · Phase 2/3 · Australia, Germany, Spain, France, United Kingdom, Italy

  Source: ClinicalTrials.gov
• 19 Jun 2026

  Status changed: Recruiting → Not yet recruiting

  A First-In Human (FIH) Study to Find Out How Well REGN10597 Medicine Given Alone or in Combination With Cemiplimab Works in Adult Participants Who Have Cancer With Tumors That Have Spread in Their Body

  NCT06413680 · Phase 1/2 · Germany, Spain, France, Italy, United States

  Source: ClinicalTrials.gov
• 3 Nov 2026

  Status changed: By invitation only → Not yet recruiting

  A Long-Term Follow-Up Study of Subjects Completing the AU-011-301(CoMpass) for Early Choroidal Melanoma

  NCT07338968 · Phase 3 · Austria, Belgium, Czechia, Germany, Spain, France

  Source: ClinicalTrials.gov
• 3 Nov 2026

  New in the registry

  A Multicentre, open label, Phase I-Ib Clinical Trial Combining Melanoma-Specific Peptide Vaccination (UniCanVax) and Anti PD-1 Inhibitor (Nivolumab) in Immune Checkpoint Blockade Refractory Metastatic or Unresectable Stage III/IV Melanoma Patients

  2025-524486-25-00 · Phase 1 · Italy

  Source: EU CTIS
• 1 Oct 2026

  Opened for recruitment

  A Study of Subcutaneous Nivolumab + Relatlimab Fixed-dose Combination (FDC) in Previously Untreated Metastatic or Unresectable Melanoma

  NCT05625399 · Phase 3 · Austria, Australia, Belgium, Brazil, Canada, Switzerland

  Source: ClinicalTrials.gov
• 30 Jan 2025

  Closed for recruitment

  Assessment of PET Tracers to Evaluate T Cell Change and Activation in Relation to Immunotherapy Treatment Response in Non-Small Cell Lung Cancer

  NCT06457789 · Phase 2/3 · Netherlands

  Source: ClinicalTrials.gov
• 2 Oct 2024

  Closed for recruitment

  A Clinical Imaging Study of the Changes in [18F]F-AraG Uptake Following Anti-PD-1 Therapy in Non-small Cell Lung Cancer

  NCT05701176 · Phase 1/2 · Netherlands

  Source: ClinicalTrials.gov
• 14 Oct 2026

  Closed for recruitment

  START: Safety and Anti-Tumor Activity of PeptiCRAd-1 in Treatment of Cancer

  NCT05492682 · Phase 1 · Germany, Italy

  Source: ClinicalTrials.gov
• 15 May 2026

  Status changed: Recruiting → Not yet recruiting

  DB-1311 in Combination With BNT327 or DB-1305 in Advanced/Metastatic Solid Tumors

  NCT06953089 · Phase 2 · Australia, China, Germany, Spain, France, Italy

  Source: ClinicalTrials.gov
• 4 Nov 2026

  Status changed: Running, not recruiting → Completed

  A Single Arm Trial Evaluating the Efficacy and Safety of EVX-01 in Combination With Pembrolizumab in Adults With Unresectable or Metastatic Melanoma

  NCT05309421 · Phase 2 · Australia, Italy

  Source: ClinicalTrials.gov
• 4 Nov 2026

  Opened for recruitment

  SI-B036-ST-101 in Advanced/Metastatic Solid Tumors

  NCT07857616 · Phase 1 · United States

  Source: ClinicalTrials.gov
• 22 Jul 2026

  Phase changed: No phase → Phase 2

  Validation of ICG-99mTc-nanoscan as Hybrid Tracer for Sentinel Node Biopsy

  NCT06666634 · Phase 2 · Netherlands

  Source: ClinicalTrials.gov
• 19 Aug 2026

  Phase changed: No phase → Phase 3

  A Long-Term Follow-Up Study of Subjects Completing the AU-011-301(CoMpass) for Early Choroidal Melanoma

  NCT07338968 · Phase 3 · Austria, Belgium, Czechia, Germany, Spain, France

  Source: ClinicalTrials.gov
• 9 Oct 2026

  Phase changed: No phase → Phase 1/2

  Long-Term Follow-up of Patients Treated With Miltenyi Cell and Gene Therapies

  NCT06508775 · Phase 1/2 · Germany

  Source: ClinicalTrials.gov
• 12 Jan 2026

  Phase changed: No phase → Phase 4

  A Study to Assess the Long-term Safety Outcomes in Patients Previously Treated With RP1, RP2, or RP3

  NCT06887348 · Phase 4 · Australia, Germany, Spain, France, Greece, Poland

  Source: ClinicalTrials.gov
• 18 Aug 2026

  Phase changed: No phase → Phase 2/3

  Assessment of PET Tracers to Evaluate T Cell Change and Activation in Relation to Immunotherapy Treatment Response in Non-Small Cell Lung Cancer

  NCT06457789 · Phase 2/3 · Netherlands

  Source: ClinicalTrials.gov
• 18 Aug 2026

  Phase changed: No phase → Phase 1/2

  A Clinical Imaging Study of the Changes in [18F]F-AraG Uptake Following Anti-PD-1 Therapy in Non-small Cell Lung Cancer

  NCT05701176 · Phase 1/2 · Netherlands

  Source: ClinicalTrials.gov

New reviews, guidelines and randomised trials in PubMed

• 4 Nov 2026

  Systematic review

  A systematic review on the possible role of microRNA-155 in cancer treatment.

  Frontiers in pharmacology · PubMed

• 31 Oct 2026

  Systematic review

  Venlafaxine in oncology: supportive-care evidence and emerging preclinical anticancer signals: a systematic review.

  Frontiers in pharmacology · PubMed

Results card

Trials that finished or stopped in the last 3 years, with the reason the registry gives and linked publications.

• Phase 1Ended 1 Oct 2026

  Completed5 participants

  NCT06941818

  HS-IT101 Injection in the Treatment of Advanced Melanoma(FASTIL-Mela01)

  Registry record

• No phaseEnded 1 Sept 2026

  Completed1334 participants

  NCT05225428

  Video Education With Result Dependent dIsclosure

  Registry record

• Phase 1/2Ended 20 Aug 2026

  Completed28 participants

  NCT03131908

  Study of the Selective PI3K-Beta Inhibitor GSK2636771 in Combination With Pembrolizumab in Patients With Metastatic Melanoma and PTEN Loss

  Registry record

• No phaseEnded 31 Jul 2026

  Completed10000 participants

  NCT07831083

  Skin Cancer Among Outdoor Workers

  Registry record

• Phase 1Ended 31 Jul 2026

  Completed18 participants

  NCT05858736

  Safety, PK and Efficacy of AI-061 in Advanced Solid Tumors

  Registry record

• Phase 1Ended 22 Jul 2026

  Completed77 participants

  NCT06131398

  A Study of AMG 355 Alone and in Combination With Pembrolizumab in Participants With Advanced Solid Tumors

  Registry record

• Phase 1Ended 16 Jul 2026

  Completed138 participants

  NCT03872947

  A Study of TRK-950 in Combinations With Anti-Cancer Treatment Regimens in Patients With Advanced Solid Tumors

  Registry record

• Phase 2Ended 9 Jul 2026

  Completed51 participants

  NCT05282901

  Efficacy and Safety of Pembrolizumab in Combination With Lenvatinib in Metastatic Uveal MElanoma Patients (PLUME)

  Registry record

• Phase 1Ended 7 Jul 2026

  Completed96 participants

  NCT06551064

  Assessment of PK Similarity of FYB206 in Comparison With Keytruda in Resected Stage II or III Melanoma Patients

  Registry record

• No phaseEnded 30 Jun 2026

  Completed7 participants

  NCT06549439

  eFLASH for Skin Lesions of Malignant Melanomas

  • The prospective phase I "Flash-Skin I" trial: ultra-high dose rate radiotherapy implementation and quality assurance at a clinical linear accelerator. · Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology, 2026
  Registry record

• Phase 2Ended 16 Jun 2026

  Completed35 participants

  NCT01972347

  Neoadjuvant Dabrafenib + Trametinib for AJCC Stage IIIB-C BRAF V600 Mutation Positive Melanoma

  Registry record

• Phase 1/2Ended 2 Jun 2026

  Completed98 participants

  NCT05864144

  A Study of SNS-101 (Anti VISTA) Monotherapy and in Combination With Cemiplimab in Patients With Advanced Solid Tumors

  Registry record

• Phase 1/2Ended 2 Jun 2026

  Completed44 participants

  NCT04386967

  OH2 Injection in Solid Tumors

  Registry record

• Phase 3Ended 26 May 2026

  Completed1150 participants

  NCT00003641

  High-Dose Interferon Alfa in Treating Patients With Stage II or Stage III Melanoma

  Registry record

• Phase 2Ended 26 May 2026

  Completed88 participants

  NCT01708941

  Ipilimumab With or Without High-Dose Recombinant Interferon Alfa-2b in Treating Patients With Stage III-IV Melanoma That Cannot Be Removed by Surgery

  Registry record

• Phase 1/2Ended 18 May 2026

  Completed335 participants

  NCT04305054

  Substudy 02B: Safety and Efficacy of Pembrolizumab in Combination With Investigational Agents or Pembrolizumab Alone in Participants With First Line (1L) Advanced Melanoma (MK-3475-02B/KEYMAKER-U02)

  Registry record

• Phase 1Ended 14 May 2026

  Completed13 participants

  NCT03336606

  Study of MEDI0562 Prior to Surgical Resection in Head and Neck Squamous Cell Carcinoma (HNSCC) or Melanoma

  Registry record

• Phase 1Ended 5 May 2026

  Completed322 participants

  NCT06153238

  A PK Study to Compare GME751 (Proposed Pembrolizumab Biosimilar) and US-licensed and EU-authorized Keytruda® in Participants With Stage II and III Melanoma

  Registry record

• Phase 2Ended 5 May 2026

  Completed120 participants

  2022-500652-37-00

  Clinical study to investigate the efficacy of botensilimab (AGEN1181) in patients with advanced melanoma refractory to prior checkpoint inhibitor therapy

  Registry record

• Phase 1Ended 5 May 2026

  Completed136 participants

  2023-506881-30-00

  A Pharmacokinetics (PK) study to compare GME751 (proposed pembrolizumab biosimilar) and United States (US)-licensed and European Union (EU)-approved Keytruda®in participants with stage Ⅱ and Ⅲ skin cancer requiring adjuvant treatment (therapy applied after initial treatment of cancer to suppress the regrowth of tumor) with pembrolizumab.

  Registry record

• Phase 1Ended 23 Apr 2026

  Completed33 participants

  2024-517756-35-00

  A study to learn about the study medicine called PF-08046032 in people with advanced cancers.

  Registry record

• Phase 1Ended 22 Apr 2026

  Completed156 participants

  NCT05479812

  Dose Escalation and Expansion Study of WTX-124 as Monotherapy and in Combination With Pembrolizumab (Pembro) in Patients With Selected Advanced or Metastatic Solid Tumors

  Registry record

• Phase 2Ended 7 Apr 2026

  Completed17 participants

  NCT05309421

  A Single Arm Trial Evaluating the Efficacy and Safety of EVX-01 in Combination With Pembrolizumab in Adults With Unresectable or Metastatic Melanoma

  Registry record

• No phaseEnded 23 Mar 2026

  Completed72 participants

  NCT05461430

  Mass Response of Tumor Cells as a Biomarker for Rapid Therapy Guidance (TraveraRTGx)

  Registry record

• Phase 2Ended 19 Mar 2026

  Completed24 participants

  NCT02816021

  Study of Oral Azacitidine (CC-486) in Combination With Pembrolizumab (MK-3475) in Patients With Metastatic Melanoma

  Registry record

• Phase 1Ended 17 Mar 2026

  Completed22 participants

  NCT06014086

  Intratumoral PH-762 for Cutaneous Carcinoma

  Registry record

• No phaseEnded 13 Mar 2026

  Completed68 participants

  NCT07506447

  The Value of [18F]FDG PET/CT Imaging in Prognostic Evaluation of Mucosal Melanoma

  Registry record

• Phase 1Ended 11 Mar 2026

  Completed9 participants

  2024-518088-37-01

  A Phase I Open-Label, Dose-escalation Clinical Trial of Tumor Necrosis Factor Alpha and Interleukin-2 Coding Oncolytic Adenovirus TILT-123 in combination with avelumab in injectable solid tumor patients (melanoma and SCCHN) refractory to or progressing after anti-PD(L)1 immunotherapy

  Registry record

• Phase 1Ended 11 Mar 2026

  Completed70 participants

  2023-506310-43-00

  A Study to Evaluate Safety, Pharmacokinetics, and Preliminary Clinical Activity of RO7276389 Alone and in Combination with Cobimetinib in Participants with BRAF-V600 Mutation-Positive Advanced Solid Tumor or BRAF-V600 Mutation-Positive Melanoma with Central Nervous System Metastases

  Registry record

• No phaseEnded 6 Mar 2026

  Completed16 participants

  NCT06919809

  Effectiveness and Safety of X A-DERM™ Microsurfaced Acellular Dermal Matrix for Wound Healing After MOHS Surgery

  Registry record

• Phase 2Ended 6 Mar 2026

  Completed216 participants

  NCT02645149

  Molecular Profiling and Matched Targeted Therapy for Patients With Unresectable Advanced or Metastatic Melanoma

  Registry record

• Phase 1Ended 4 Mar 2026

  Completed26 participants

  NCT04495257

  A Study of APX005M in Combination With Nivolumab and Ipilimumab in Treatment Naïve Patients With Advanced Melanoma or Renal Cell Carcinoma (RCC)

  Registry record

• Phase 3Ended 2 Mar 2026

  Completed266 participants

  NCT06320353

  Study сomparing the Efficacy and Safety of RPH-075 and Keytruda® in Patients With Unresectable or Metastatic Skin Melanoma

  Registry record

• No phaseEnded 28 Feb 2026

  Completed1 participants

  NCT07651020

  The Clinical Application Value of SPECT Imaging Targeting LRRC15 in Malignant Tumors

  Registry record

• No phaseEnded 15 Feb 2026

  Completed32 participants

  NCT04890028

  Detection and Metabolic Characterization in DOPA PET/CT of Brain Metastases

  Registry record

• No phaseEnded 9 Feb 2026

  Completed190 participants

  NCT04146064

  Breathomics as Predictive Biomarker for Checkpoint Inhibitor Response

  Registry record

• Phase 2Ended 3 Feb 2026

  Completed161 participants

  NCT04609566

  Brentuximab Vedotin With Pembrolizumab in Metastatic Solid Tumors

  Registry record

• Phase 2Ended 2 Feb 2026

  Completed119 participants

  2023-509471-17-00

  Phase 2 Study of Encorafenib and Binimetinib Plus Pembrolizumab in Participants With BRAF V600E/K Mutation-Positive Melanoma Who Progressed During or After Prior Treatment with Anti−PD-1 Therapy

  Registry record

• No phaseEnded Jan 2026

  Completed14 participants

  NCT02724488

  Selection Pressure and Evolution Induced by Immune Checkpoint Inhibitors and Other Immunologic Therapies

  Registry record

• No phaseEnded 30 Jan 2026

  Completed187 participants

  NCT02910557

  Postmarketing Prospective Study of Melanoma Patients Treated With IMLYGIC® to Characterize Risk of Herpetic Infection

  Registry record

• Phase 2Ended 28 Jan 2026

  Completed65 participants

  2022-502787-20-00

  Phase II, multi‑cohort trial of neoadjuvant and post‑surgery IO102‑IO103 and pembrolizumab in patients with selected resectable tumors

  Registry record

• No phaseEnded 27 Jan 2026

  Completed627 participants

  NCT04726319

  Family History App in Personalized Medicine

  Registry record

• No phaseEnded 23 Jan 2026

  Completed64 participants

  NCT03707574

  Genetic Analysis of Blood and Tissue Samples From Patients With Advanced Cancer, Moonshot Study

  Registry record

• Phase 2Ended 19 Jan 2026

  Completed129 participants

  NCT06984328

  Study of the Effectiveness and Safety of Acasunlimab Alone or With Pembrolizumab in treating Advanced Melanoma of the Skin That Has Returned After or did not respond to Cancer Immunotherapy (ABBIL1TY MELANOMA-07)

  Registry record

• Phase 2Ended 15 Jan 2026

  Completed38 participants

  NCT04225390

  Preconditioning of Tumor, Tumor Microenvironment and the Immune System to Immunotherapy

  Registry record

• Phase 2Ended 15 Jan 2026

  Completed45 participants

  2024-517065-16-00

  A Phase 2, single arm study on dacarbazine (DTIC) followed by immunotherapy re-challenge in unresectable or metastatic melanoma with primary resistance to PD-1/PD-L1 or PD-1 + CTLA-4 blockade (PROMIT: PReconditioning of TumOr, Tumor Microenvironment and the Immune System to ImmunoTherapy)

  Registry record

• Phase 2Ended 4 Jan 2026

  Completed27 participants

  NCT04552223

  Nivolumab Plus Relatlimab in Patients With Metastatic Uveal Melanoma

  Registry record

• No phaseEnded 31 Dec 2025

  Completed30 participants

  NCT06384417

  Using an End-of-life Conversation Game to Engage Patients With Cancer in Advance Care Planning: Phase 2

  Registry record

• Phase 1Ended 31 Dec 2025

  Completed20 participants

  NCT03021460

  Pembrolizumab and Ibrutinib in Treating Patients With Stage III-IV Melanoma That Cannot Be Removed by Surgery

  Registry record

• Phase 2Ended 31 Dec 2025

  Completed24 participants

  NCT02636569

  Topical Chemoprevention of Skin Cancer Biomarkers

  Registry record

• No phaseEnded 31 Dec 2025

  Completed549 participants

  NCT04593277

  Interactive Survivorship Program for the Improvement of Healthcare Resources in Adolescent and Young Adult Cancer Survivors, INSPIRE-AYA Study

  Registry record

• Phase 1/2Ended 18 Dec 2025

  Completed40 participants

  NCT05708950

  A Clinical Trial of KVA12123 [TBS-2025] Treatment Alone and in Combination With Pembrolizumab In Advanced Solid Tumors (VISTA-101)

  Registry record

• Phase 1Ended 18 Dec 2025

  Completed140 participants

  NCT00600496

  A Phase I, Open-Label, Multi-center Study to Assess the Safety, Tolerability and Pharmacokinetics of AZD6244 (ARRY-142886)

  Registry record

• Phase 2Ended 15 Dec 2025

  Completed26 participants

  NCT03405155

  Nivolumab in Treating Patients With Stage IIB-IIC Melanoma That Can Be Removed by Surgery

  Registry record

• Phase 2Ended 11 Dec 2025

  Completed64 participants

  NCT04091022

  Topical Diclofenac and Topical DFMO Chemoprevention Trial in Subjects With a History of Skin Cancer

  Registry record

• No phaseEnded 9 Dec 2025

  Completed152 participants

  NCT03771859

  A Study of Patients Receiving Adjuvant Nivolumab Therapy for Melanoma That Has Been Removed

  Registry record

• Phase 1Ended 8 Dec 2025

  Completed5 participants

  NCT06894771

  A Study of MK-4700 Alone or With Pembrolizumab in Participants With Advanced or Metastatic Solid Tumors (MK-4700-001)

  Registry record

• Phase 1/2Ended 4 Dec 2025

  Completed281 participants

  NCT03400332

  A Study of BMS-986253 in Combination With Nivolumab or Nivolumab Plus Ipilimumab in Advanced Cancers

  Registry record

• Phase 1Ended 4 Dec 2025

  Completed35 participants

  NCT06108479

  Study of DF6215 in Patients With Advanced Solid Tumors

  Registry record

• Phase 2Ended 3 Dec 2025

  Completed52 participants

  2024-515850-26-00

  PET-DOPA Metabolic Detection and Characterization of Untreated Brain Metastases of Bronchial, Breast and Melanoma Cancer

  Registry record

Not medical advice. fetched 6 Nov 2026